IDH1 / IDH Antibody (aa280-420, clone IDH1/1152, Azide-free, BSA-free)

LifeSpan BioSciences

IDH1 / IDH Antibody (aa280-420, clone IDH1/1152, Azide-free, BSA-free)

23

The applications listed have been tested for the unmodified form of this product. Other forms have not been tested. It recognizes a 45kDa protein, which is identified as isocitrate dehydrogenase (IDH1). It belongs to the isocitrate and isopropylmalate dehydrogenases family. IDH1 catalyzes the third step of the citric acid cycle, which involves the oxidative decarboxylation of isocitrate, forming a-ketoglutarate and CO2 in a two-step reaction. The first step involves the oxidation of isocitrate to the intermediate oxalosuccinate, while the second step involves the production of a-ketoglutarate. During this process, either NADH or NADPH is produced along with CO2. Recently, an inactivating mutation of IDH1 has been implicated in glioblastoma. IDH1 appears to function as a tumor suppressor that, when mutationally inactivated, contributes to tumorigenesis in part through induction of the HIF-1 pathway. Optimal dilution of the IDH1 antibody should be determined by the researcher. Staining of formalin-fixed tissues requires boiling tissue sections in 10mM Tris with 1mM EDTA, pH 9.0 or 10mM Citrate buffer, pH 6.0, for 10-20 min followed by cooling at RT for 20 min.. Flo (0.5 - 1 µg/10E6 cells), IF (0.5 - 1 µg/ml), IHC, IHC-P (0.5 - 1 µg/ml), WB (0.5 - 1 µg/ml) The applications listed have been tested for the unmodified form of this product. Other forms have not been tested. It recognizes a 45kDa protein, which is identified as isocitrate dehydrogenase (IDH1). It belongs to the isocitrate and isopropylmalate dehydrogenases family. IDH1 catalyzes the third step of the citric acid cycle, which involves the oxidative decarboxylation of isocitrate, forming a-ketoglutarate and CO2 in a two-step reaction. The first step involves the oxidation of isocitrate to the intermediate oxalosuccinate, while the second step involves the production of a-ketoglutarate. During this process, either NADH or NADPH is produced along with CO2. Recently, an inactivating mutation of IDH1 has been implicated in glioblastoma. IDH1 appears to function as a tumor suppressor that, when mutationally inactivated, contributes to tumorigenesis in part through induction of the HIF-1 pathway. Optimal dilution of the IDH1 antibody should be determined by the researcher. Staining of formalin-fixed tissues requires boiling tissue sections in 10mM Tris with 1mM EDTA, pH 9.0 or 10mM Citrate buffer, pH 6.0, for 10-20 min followed by cooling at RT for 20 min.

Flow Cytometry, ImmunoFluorescence, Western Blot, ImmunoHistoChemistry, ImmunoHistoChemistry Paraffin

Research Use Only

Monoclonal

IDH1/1152

1 mg/ml

Unconjugated

...

IDH1

isocitrate dehydrogenase (NADP(+)) 1

epididymis luminal protein 216; epididymis secretory protein Li 26; epididymis secretory sperm binding protein; HEL-216; HEL-S-26; IDCD; IDH; IDP; IDPC; isocitrate dehydrogenase (NADP(+)) 1, cytosolic; isocitrate dehydrogenase [NADP] cytoplasmic; isocitrate dehydrogenase 1 (NADP+), soluble; NADP(+)-specific ICDH; NADP-dependent isocitrate dehydrogenase, cytosolic; NADP-dependent isocitrate dehydrogenase, peroxisomal; oxalosuccinate decarboxylase; PICD

Mouse

IgG1

2°C to 8°C

12352203